Hypertension contributes to increased morbidity and mortality in the chronic kidney disease (CKD) population. Studies on blood pressure control in CKD patients in China are limited. In this study, we aimed to describe the status of blood pressure control in Chinese CKD patients based on the first national prospective CKD cohort data.
Original article
Chronic kidney disease (CKD) is a major public health concern for China. 1 A recent national survey has demonstrated that the prevalence of CKD reached 10.8%, which is equivalent to 119.5 million people. 2 Hypertension is very prevalent in CKD and is a determinant of CKD progression. Some large-scale studies of CKD patients have demonstrated that the prevalence of hypertension is very high; i.e., 86.2% in the Kidney Early Evaluation Program study, 3 and 67.3% in a hospital-based multicenter study among Chinese CKD patients. 4 The corresponding prevalence is much lower in the general population; it was reported to be 18% by the 2002 National Health and Nutrition Survey in China. 5 Although hypertension is widely recognized as an independent risk factor for the development and progression of CKD, 6,7 study of hypertension control in CKD patients is limited in China. Increased efforts are needed to identify the reasons for inadequate hypertension control and approaches to increase blood pressure control among patients with CKD.
The Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE) study, the first national prospective CKD cohort of the Chinese population, was established to examine risk factors for progression of CKD and cardiovascular disease among CKD patients. The aim of the present study was to investigate factors associated with hypertension control based on C-STRIDE baseline visit data.
The C-STRIDE study is an ongoing multicenter cohort of the Chinese predialysis CKD patients with a broad spectrum of renal disease severity, which includes 39 hospitals located at 28 cities in 22 provinces of China. Participants with CKD stage 1 to 4, 18 to 74 years of age, were enrolled in the C-STRIDE. Inclusion into the study was based on CKD etiology-specific estimated glomerular filtration rate (eGFR) levels that were calculated using serum creatinine: eGFR ≥15 ml/min/1.73 m 2 for patients with chronic glomerulonephritis and 15 ≤ eGFR < 60 ml/min/1.73 m 2 for nonglomerulonephritic patients. The C-STRIDE design was described in detail previously. 8 The study was initiated in November 2011 with the aim of enrolling 3,000 predialysis CKD patients and scheduled follow-up for at least 5 years. Questionnaires, anthropometric measures, laboratory tests, and biomaterials were collected at baseline and annually. The principal clinical outcomes of C-STRIDE can be broadly categorized as renal disease events, cardiovascular events, and death. A total of 3,472 participants were included until June 2016, of whom 2,873 participants with complete record on blood pressure measurement and/or antihypertensive medication histories. We studied a subgroup of 2,251 subjects from C-STRIDE participants who had hypertension at enrollment. The C-STRIDE study was approved by the ethics committee of Peking University First Hospital and was in adherence with the Declaration of Helsinki. All participants gave written informed consent before data collection.
Blood pressure measurements
Participants were advised to refrain from coffee, tea, or alcohol intake, cigarette smoking, and vigorous exercise for at least 90 minutes prior to their examination. Three blood pressure measurements were obtained in a sitting position after at least 5 to 10 minutes of quiet rest by trained staff according to a standard protocol. A mercury sphygmomanometer was used with an appropriate cuff size based on the participant's right upper arm circumference and supported at the heart level. Systolic blood pressure was determined at the onset of Korotkoff phase I, and diastolic blood pressure was determined at Korotkoff phase V. Blood pressure was measured 3 times at 5-minute intervals and 3 readings were averaged.
Data collection
During the study visit, all C-STRIDE study data were collected by trained staff according to the study protocol. Data were obtained by questionnaires documenting sociodemographic status, personal and family health history, and lifestyle of the participants. Anthropometric measurements, collection of blood specimens, and spot urine as well as a 24-hour urine sample were obtained. Blood biochemical indexes, intact parathormone, spot urine albumin, urine creatinine, and 24-hour urinary electrolyte excretion were measured at the central laboratory. The spot urine albumin/ creatinine ratio (ACR) was calculated. GFR was estimated from serum creatinine measurements and demographic characteristics by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. 9 The numbers and amount of antihypertensive drugs were documented.
All study investigators and staff members completed a training program for methods and processes of the study. A manual of procedures was distributed, and detailed instructions for administration of the questionnaires, blood pressure and anthropometric measurements, and biological specimen collection and processing were provided.
Definitions
According to the K/DOQI guidelines, 10 CKD was defined as eGFR <60 ml/min/1.73 m 2 and/or the presence of kidney damage, indicated by elevated urine albumin excretion. Participants were stratified into 4 stages based on GFR values: stage 1 (≥90 ml/min per 1.73 m 2 ), stage 2 (60-89 ml/min per 1.73 m 2 ), stage 3 (30-59 ml/min per 1.73 m 2 ), and stage 4 (15-29 ml/min per 1.73 m 2 ). Based on the average of 3 blood pressure measurements, hypertension was defined as systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg and/or current antihypertensive medication use as reported on the baseline study questionnaire. Participants who had been diagnosed as having hypertension were considered to be aware of their hypertension. Participants were considered as being treated if they were taking antihypertensive drugs. Blood pressure control was defined based on the Eighth Joint National Committee (JNC 8), 11 a goal BP of less than 140/90 mm Hg for CKD patients was suggested. Uncontrolled blood pressure was defined as systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg.
Smoking was defined as currently smoking or had ever smoked. Alcohol consumption was defined as a habitual drinker (drink once a day or more) vs. nonhabitual drinker (5 times per week to once a month) vs. nondrinker (almost never). Hyperuricemia was defined as >422 µmol/l for men and >363 µmol/l for women. Diabetes mellitus was defined as a plasma glucose ≥7.0 mmol/l after fasting for a minimum of 8 hours, and/or self-reported physician diagnosis or current use of insulin or antidiabetes medication. Insurance status was defined as any coverage. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. Patients were categorized as underweight (BMI < 18.5 kg/m 2 ), normal weight (18.5-23.9 kg/m 2 ), overweight (24.0-27.9 kg/m 2 ), or obese (≥28 kg/m 2 ). Antihypertensive medications were classified according to their mechanism of action (renin-angiogensin blocker [RAS blocker] including angiotensin-converting enzyme inhibitors or angiotensin receptor blockers), β-blockers and calcium-channel blockers, and diuretics including loop-, thiazide-, and potassiumsparing types. Monotherapy was defined as a person who reported using only one antihypertensive agent. Polytherapy (combination therapy) was defined as a person who reported using more than 1 antihypertensive drug. Subjects who received antihypertensive treatment but were unaware of the dose or drug type were labeled as unknown.
Single-pill combinations were separated into their generic components. Each medication was classified into only 1 category. The sum of BP medication categories defined the number of antihypertensive medications taken by each patient. Defined daily doses (DDDs) are used as a standard for measuring drug utilization and exposure in a population. The World Health Organization (WHO) 12 defines DDD as the assumed average maintenance dose per day for a drug used for its main indication in adults. For example, 50 mg of losartan, 5 mg of amlodipine, or 150 mg of metoprolol daily was defined as 1 DDD, respectively. Therefore, daily administration of 50 mg of losartan, 5 mg of amlodipine, and 150 mg of metoprolol equals 3 DDDs. The DDD system provides a fixed unit of measurement independent of price and formulation, enabling the researcher to assess trends in drug consumption and to perform comparisons between population groups.
Statistical analysis
Continuous data were presented as mean ± SD except for urine ACR and 24-hour urinary sodium (UNa) excretion, which were presented as medians (interquartile range) due to significant skewness. Categorical variables were presented as proportions. For univariate analysis, characteristics of hypertensive individuals with controlled hypertension were compared with those with uncontrolled hypertension. Moreover, an analysis was conducted by evaluating the number and amount of antihypertension medications taken for individuals between groups. A chi-squared test was used to compare frequencies between groups, and a Student's t-test or 1-way analysis of variance was used to compare differences in means for continuous variables. In addition, a multiple logistic regression model was used to assess the association of several demographic and clinical characteristics with uncontrolled hypertension. Covariates included in the multivariable logistic regression models were age (18-44 years vs. 45-64 years vs. ≥65 years), 13 sex, annual income (per one thousand; <30 vs. 30-50 vs. 50-100 vs. >100), education (≥high school vs. <high school), insurance (yes vs. no), smoker (yes vs. no), alcohol intake (nondrinker vs. habitual drinker vs. nonhabitual drinker), BMI (<18.5 vs. 18.5-23.9 vs. 24-27.9 vs. ≥28), ACR (<30 mg/g vs. 30-300 mg/g vs. >300 mg/g), hyperuricemia (>422 µmol/l for men, >363 µmol/l for women), eGFR (≥90 ml/min vs. 60-89 ml/min vs. 30-59 ml/min vs. <30 ml/ min), and diabetes (yes vs. no). Odds ratios (ORs) and 95% confidence intervals (CIs) are reported. Probability values of P less than 0.05 (2-sided) were considered statistically significant. All analyses were performed using SAS software, version 9.1.3 (SAS Institute, Cary, NC).
RESULTS

Characteristics of the hypertensive C-STRIDE participants
There were 2,251 hypertensive CKD subjects among a total of 2,873 C-STRIDE participants at baseline. Overall, the prevalence of hypertension was 78.4%. The hypertension awareness, treatment, and control rates of the hypertensive CKD patients were 80.7%, 95.6%, and 57.1%, respectively. The awareness rate of hypertension increased and the control rate decreased in those patients who were male, with a higher BMI and lower eGFR. As age progresses, the hypertension awareness rate increased, but there was no difference in treatment and control rates among the different age groups. Although less educated participants were more aware of their hypertension state, they were less likely to receive antihypertensive treatment and had lower blood pressure control than those with higher education (Table 1) . A summary of demographic, socioeconomic, and clinical characteristics of C-STRIDE hypertensive participants is presented in Table 2 . The mean age of the hypertensive CKD individuals was 49.5 ± 13.2 years and 62.0% were male.
Compared to the hypertension controlled group, the uncontrolled population was more likely to be male, less educated, with greater BMI, higher systolic and diastolic blood pressure , more albuminuria, a higher uric acid level and lower eGFR. Those with hypertension inadequately controlled increased with advancing CKD stages (8.5% for participants with eGFR ≥ 90 ml/min to 35.3% for those with eGFR <30 ml/min; P < 0.001). More people had diabetes in the uncontrolled hypertension group compared to the controlled hypertension group ( Table 2) .
Prescriptions of antihypertensives in the hypertensive C-STRIDE participants
RAS blocker and calcium-channel blockers were the most commonly used antihypertensive medications among C-STRIDE hypertensive participants, with the proportion of prescriptions as 59.5% and 59.4%, respectively. The following were beta-blockers and diuretics with proportions of 22.9% and 7.3%, respectively. Among hypertensive C-STRIDE participants, 34.2%, 31.8%, and 20.7% were taking 1, 2, and 3 or more antihypertensive medications, respectively. The mean DDD of antihypertensive drugs among C-STRIDE hypertensive adults was 1.6 (1.0, 2.7). Uncontrolled hypertensive patients were prescribed less antihypertensive medication in amount than controlled hypertensives (DDD 1. (Table 4) .
Factors of uncontrolled hypertension
After multivariable adjustment, overweight and obesity were found to be associated with the status of uncontrolled hypertension with an OR of 1.4 (95% CI: 1.1-1.7) and 2.2 (95% CI: 1.7-2.9), respectively. Other risk factors were ACR (>300 mg/g, OR: 2.0, 95% CI: 1.4-2.9), decreased eGFR (60-89 ml/min, OR: 1.8, 95% CI: 1.2-2.8; 30-59 ml/min, OR: 2.0, 95% CI: 1.4-3.0; <30 ml/min, OR: 2.7, 95% CI: 1.8-4.1) and diabetes (OR: 1.4, 95% CI: 1.1-1.8). No specific antihypertensive class was independently associated with blood pressure control (Table 5) .
DISCUSSION
Hypertension is a common comorbidity affecting the vast majority of patients with CKD. 14 Adequate control remains suboptimal. In this sample of Chinese patients with CKD, 57.1% achieved the blood pressure target advocated by JNC8 (<140/90 mm Hg). It is very important to find the reasons for the uncontrolled blood pressure and slow the progressive decline in kidney function.
In the current study, the prevalence of hypertension in CKD patients was greater than that among the general population (78.4% vs. 29.6%) and similar higher prevalences were found for awareness, treatment, and control rates in C-STRIDE participants compared with those of the general population (80.7% vs. 42.6%, 95.6% vs. 34.1%, and 57.1% vs. 9.3%, respectively). 15 A large population-based cohort study showed that there is a high prevalence of hypertension in patients with CKD. 16 Higher hypertension awareness, treatment, and control rates in the CKD population may be because individuals with CKD were more conscious of their blood pressure and more likely to receive antihypertensive therapy than non-CKD adults. We compared data of the C-STRIDE with the national survey for the CKD population in 2004-2005, 17 and found, although hypertension awareness was somewhat decreased in the C-STRIDE study compared to that in 2004-2005 (80.7% vs. 87.2%), there were significant improvements with hypertension treatment and control rates across the 2 surveys periods (95.6% vs. 85.9% and 57.1% vs. 30.0%, respectively). The results may reflect improvement of people's economic status and health literacy over time. Clinical feedback may also play a key role in improving hypertension control. In the present study, the hypertension awareness rate was 80.7%, but treatment rate of the hypertensive CKD patients was 95.6%. That means almost 15.0% hypertensive CKD patients were prescribed antihypertensive medications without aware of their hypertension condition. Moreover, the hypertension awareness rate in C-STRIDE study did not increase with time compared to that in [2004] [2005] . Therefore, the importance of undertaking strategies to increase awareness of hypertension in CKD patients should be highlighted. Although these improvements were observed, hypertension control was still suboptimal compared with developed countries. The prevalence of hypertension treatment reported in our study was comparable to that reported in the Chronic Renal Insufficiency Cohort (CRIC) study (95.6% vs. 98.3%), but the awareness and control rates were much lower in the Chinese CKD population than in the American CKD population (80.7% vs. 98.9% and 57.1% vs. 67.1%, respectively). 18 Achieving appropriate control of hypertension requires an understanding of the modifiable factors for blood pressure Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB, β-blockers; CCB, calcium-channel blocker; CKD, chronic kidney disease; DDDs, defined daily doses. Values are reported as mean ± SD or percentages. Abbreviations: ACR, albumin/creatinine ratio; BMI, body mass index; CKD, chronic kidney disease; DBP, dystolic blood pressure; eGFR, estimated glomerular filtration rate; IQR, interquartile range; SBP, systolic blood pressure; UNa, urine sodium. 19 In multivariable logistic analyses, overweight, obesity, higher ACR, decreased eGFR, and diabetes were independent factors for uncontrolled blood pressure in the current study. In other Asian nations, such as Japan and South Korea, obesity, albuminuria, and diabetes were found to be the associated risk factors for uncontrolled hypertension in the CKD population. 20, 21 In the CRIC study, diabetes and urine protein were also independent factors of suboptimal blood pressure control. 18 Data on blood pressure control with CKD stage progression are conflicting. Our study indicated the control rate decreased with advancement of CKD, which was consistent with a previous study of CKD patients in China. 22 However, in the CRIC results, there was a lack of association between eGFR and hypertension control. 18 In the Kidney Early Evaluation Program (KEEP) study, patients with stage 4 and 5 had a 3-fold higher blood pressure control rate than those with stage 1. The reason might be increases in hypertension awareness and more aggressive treatment among participants with a lower eGFR. 3 In short, successful blood pressure control in these high-risk groups may be more difficult and require more antihypertensive medications compared with controlled hypertensive people.
The lack of association between some expected factors and hypertension control in our study warrants discussion. We found that urinary sodium excretion was not associated with blood pressure control in hypertensive CKD participants. Some clinical trials and studies have convincingly demonstrated that CKD patients are particularly salt sensitive and increased sodium intake leads to higher blood pressure. 23 Salt restriction reduced blood pressure in a statistically significant and clinically important manner for patients with moderateto-severe CKD. 24, 25 However, other studies suggested that urinary sodium excretion did not predict clinically important renal outcomes. Their findings did not support routine low sodium diets for the prevention of renal outcomes in people with or without CKD. 26 The lack of association between urinary sodium and blood pressure control in our study may be that urinary sodium excretion may not fully reflect sodium intake, especially in CKD patients. McQuarrie's group reported that CKD patients with lower eGFRs had lower urinary sodium, particularly for CKD stage 5. The urine sodium to creatinine ratio increased with progressive CKD. 27 Our data were based on cross-sectional associations from a baseline analysis of an ongoing cohort study, which makes it impossible to draw an inference of causal relationship between blood pressure control and associated factors. More studies are needed to explore this relationship in follow-up data.
Our results also demonstrated the status of antihypertensive medications consumed by CKD patients. We noted that 50% of subjects were prescribed ≥2 antihypertensive therapies. This is indeed important as the majority of hypertensive patients with CKD require 2 or more antihypertensive drugs to achieve blood pressure targets. 28 A RAS blocker was the most commonly used antihypertensive medication among C-STRIDE hypertensive participants as other studies recommended. 29, 30 There may be 2 reasons for suboptimal blood pressure control with antihypertensive drugs in C-STRIDE participants. First, Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ACR, albumin/creatinine ratio; ARB, angiotensin receptor blocker; BB, β-blockers; BMI, body mass index; CCB, calcium-channel blocker; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate. participants in the uncontrolled group took less antihypertensive drugs than the controlled group: the DDD for the uncontrolled group was 1.3 (95% CI, 1.0 to 2.3) vs. 2.0 (95% CI, 1.0 to 3.1) for the controlled group. Second, diuretics were rarely used to lower blood pressure even though they are recommended as effective therapies. 31, 32 As functioning nephrons are fewer, greater doses of diuretics are required to maintain sodium and fluid homeostasis and achieve blood pressure targets. Morales' group 33 showed diverse diuretic regimens differentially decreased albuminuria, blood pressure, and body weight and enhanced the antialbuminuric effect of RAS blockers. So, diuretics should be emphasized for hypertensive CKD patients.
A major strength of our study was that it included a subgroup of the first national prospective CKD cohort of the Chinese population with great etiology heterogeneity, and therefore provides a unique data set with which to explore the status and associated risk factors of hypertension control among CKD patients. Our study had some limitations. Baseline analysis was cross-sectional, which prevented our drawing conclusions on the temporal relationships of these observations. In addition, the C-STRIDE study population was identified mostly through physicians and clinical databases. Therefore, the results are not representative of the whole population with nondialysis CKD. Furthermore, medical compliance with medication was self-reported in our study. This may have implications for the study of antihypertensive drugs in this population.
In conclusion, among Chinese hypertensive CKD patients, hypertension control is far from optimal, especially among those with obesity, albuminuria, lower eGFR, and diabetes. We may improve hypertension control for Chinese CKD patients by increasing drug education and by offering aggressive antihypertensive treatment to reach blood pressure goals. Also, patients can be advised to lose weight and manage diabetes to slow renal damage and help stabilize blood pressure.
